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The deSUMOylase SENP2 coordinates
homologous recombination and
nonhomologous end joining
by independent mechanisms
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Hannah L. Mackay, Mohammed Jamshad, Katarzyna Starowicz, Manuel Daza-Martin,
George E. Ronson, Alexander J. Lanz, James F. Beesley, and Joanna R. Morris
Birmingham Centre for Genome Biology, Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston,
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SUMOylation (small ubiquitin-likemodifier) in theDNAdouble-strand break (DSB) response regulates recruitment,
activity, and clearance of repair factors. However, our understanding of a role for deSUMOylation in this process is
limited. Here we identify different mechanistic roles for deSUMOylation in homologous recombination (HR) and
nonhomologous end joining (NHEJ) through the investigation of the deSUMOylase SENP2. We found that regulated
deSUMOylation of MDC1 prevents excessive SUMOylation and its RNF4-VCP mediated clearance from DSBs,
thereby promoting NHEJ. In contrast, we show that HR is differentially sensitive to SUMO availability and SENP2
activity is needed to provide SUMO. SENP2 is amplified as part of the chromosome 3q amplification in many
cancers. Increased SENP2 expression prolongs MDC1 focus retention and increases NHEJ and radioresistance.
Collectively, our data reveal that deSUMOylation differentially primes cells for responding to DSBs and demon-
strates the ability of SENP2 to tune DSB repair responses.
[Keywords: DNA repair; homologous recombination; MDC1; nonhomologous end joining; RNF4; SENP2; SUMO]
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The cellular response to DNA double-strand breaks
(DSBs) comprises multiple steps; sensing and signaling
the lesion, mediating the correct type of repair, clearing
repair proteins, and reforming chromatin. The response
involves a diverse set of signaling pathways and repair
mechanisms coordinated by posttranslational modifi-
cations (PTMs) including phosphorylation, acetylation,
ubiquitination, SUMOylation (small ubiquitin-like modi-
fier), and others.
Amajor consequence of SUMOylation is the promotion
of protein:protein interactions mediated by simple and
short hydrophobic SUMO interaction motifs (SIMs) on
proximal proteins (Song et al. 2004; Hecker et al. 2006;
Psakhye and Jentsch 2012). In the yeast DNA damage re-
sponse, a SUMO conjugation wave brought about by the
interaction of the E3 SUMO ligase Siz2 with DNA and
Mre11 results in modification of protein groups, thereby
promoting SUMO–SIM interactions between members
of those groups (Psakhye and Jentsch 2012; Jentsch and
Psakhye 2013; Chen et al. 2016). In humans, modification
by SUMO E3 ligases PIAS1/4 (protein inhibitor of activat-
ed STAT) and CBX4 coordinate the repair response, driv-
ing the localization, activity, and stability of many
signaling and repair proteins, such as RNF168, BRCA1,
XRCC4, and Ku70 (Yurchenko et al. 2006, 2008; Galanty
et al. 2009; Morris et al. 2009; Li et al. 2010; Danielsen
et al. 2012; Ismail et al. 2012; Luo et al. 2012; Yin et al.
2012; Hang et al. 2014; Lamoliatte et al. 2014; Tammsalu
et al. 2014). It also fosters key steps such as SUMO-BLM
and SUMO-RPA70/RPA1 mediated promotion of
RAD51 accumulation (Eladad et al. 2005; Ouyang et al.
2009; Dou et al. 2010; Shima et al. 2013).ManyDSB repair
factors are SUMOylated, but we currently lack under-
standing of specific roles for many of these modifications
(for review, see Garvin and Morris 2017).
In theDSB repair response SUMOylation is closely inte-
grated with ubiquitin (Ub) signaling and the Ub–protea-
some system (for review, see Morris and Garvin 2017).
This involves SUMO targeted Ub ligases (STUbLs), that
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bear tandem SIMmotifs and recognize poly-SUMOylated
or multimono-SUMOylated proteins and target them
for ubiquitination and subsequent degradation. Human
STUbLs include RNF111/Arkadia (Poulsen et al. 2013)
and RING finger 4 (RNF4) (Tatham et al. 2008). Processing
of SUMOylated proteins byRNF4 is part of the correct pro-
gression of DSB signaling and SUMOylation of MDC1
(mediator of damage checkpoint 1), RIF1 and BRCA1–
BARD1 result in their interaction with RNF4 and subse-
quent degradation after DNA damage (Galanty et al.
2012; Luo et al. 2012; Yin et al. 2012; Vyas et al. 2013;
Kumar and Cheok 2017; Kumar et al. 2017). RNF4 may
also regulate RPA residency on ssDNA (Galanty et al.
2012; Yin et al. 2012).
Enzymes with the ability to counter SUMO and Ub
modifications have the potential to regulate DNA damage
signaling andDNA repair. However, sincemany SUMOy-
lated factors, and the SUMO machinery itself (Kumar
et al. 2017) are eventually processed by STUbLs and de-
graded by the proteasome, it is also possible that the rever-
sal of SUMO conjugation plays only a minor role in the
response. Characterization of deubiquitinating enzymes
has shown tremendous diversity and complexity in Ub
regulation of the response (Nishi et al. 2014; Uckelmann
and Sixma 2017) but the extent of deSUMOylation en-
zyme involvement is not known.
Hereweestablish twomechanismsofDSB repair regula-
tion by the sentrin-specific protease 2, SENP2. First, we
uncover a specific requirement for SENP2 in promoting
early DSB signaling by protectingMDC1 from inappropri-
ate SUMOylation and consequent RNF4-VCP (valosin-
containing protein/p97) processing. We show interaction
between SENP2 andMDC1 is released on damage to allow
MDC1 SUMOylation required for its clearance. Second,
we reveal that homologous recombination (HR) repair
has a greater need for SUMO conjugates than nonhomolo-
gous enjoining (NHEJ), and thus requires SUMOproteases
to contribute to the supply or redistribution of SUMO.We
propose that deSUMOylation is critical to the tuning of
both major DSB repair pathways.
Results
SENP2 promotes DNA damage signaling
and DNA repair
In a prior siRNA screen of SUMO proteases using inte-
grated reporters to measure HR and NHEJ we noted that
siRNA to SENP2 resulted in impairment of both repair
pathways (Garvin et al. 2013). To address whether
SENP2 has a role in DNA repair we compared irradia-
tion (IR)-induced γH2AX (pSer139-H2AX) focus clear-
ance, indicative of DNA repair (Supplemental Fig.
S1A), and cellular sensitivity to irradiation or campto-
thecin (CPT) of wild-type and SENP2 CRISPR knockout
HAP1 cells (SENP2 knockout) (Supplemental Fig. S1B–
D). SENP2 knockout cells showed both delay in IR in-
duced γH2AX focus clearance and greater sensitivity
to DNA damaging agents than wild-type cells (Supple-
mental Fig. S1A–D).
SENP2 localizes to several subcellular compartments
and is enriched at nuclear pores (Hang and Dasso 2002;
Zhang et al. 2002; Panse et al. 2003; Makhnevych et al.
2007; Goeres et al. 2011; Chow et al. 2014; Tan et al.
2015; Odeh et al. 2018). We generated a siRNA-resistant
SENP2WT catalyticmutant (C548A) and amutantwith re-
duced nuclear pore targeting (NPm, as described previous-
ly) (illustrated inSupplemental Fig. S1E;Goeres et al. 2011;
Odeh et al. 2018). Depletion of SENP2 in HeLa resulted in
radio-sensitivity that could be complemented with
siRNA-resistant SENP2WT and SENP2NPm but not by
SENP2C548A in colony assays (Fig. 1A; Supplemental Fig.
S1F). Survival in response to CPT and olaparib and mea-
sures of both HR and NHEJ repair were also dependent
on the catalytic activity of SENP2 (Fig. 1B,C; Supplemen-
tal Fig. S1G). These data illustrate a need for catalytically
competent SENP2 in DNA DSB repair.
SUMO1 and SUMO2/3 colocalize with γH2AX foci in
response to genotoxic stress such as IR (Galanty et al.
2009; Morris et al. 2009); however, following IR, we ob-
served less SUMO colocalization in siSENP2 cells (Fig.
1D; Supplemental Fig. S1H). Since a potential cause of
SUMOconjugate loss atDSBs is a reduction in the recruit-
ment of proteins on which SUMOylation occurs (Galanty
et al. 2009; Morris et al. 2009), we examined cells for DSB
repair factor foci. MDC1 is recruited to γH2AX and begins
a Ub signaling cascade involving the E3 Ub ligases RNF8/
RNF168 to promote the recruitment of the BRCA1-A
complex and 53BP1 complex (for review, see Panier and
Boulton 2014). In siSENP2 cells MDC1 colocalization
with γH2AX was observed shortly after IR; however,
RNF8, RNF168, Ub conjugates linked through Lys63
(K63-Ub), 53BP1, and BRCA1 showed incomplete, or se-
verely reduced, recruitment (Fig. 1E). Together these data
indicate a role for SENP2 in early DSB signaling.
RNF4-VCP is responsible for defective DNA damage
signaling in SENP2-depleted cells
To determine the signaling breakpoint in SENP2-deficient
cells,we examinedMDC1,GFP-RNF168, and 53BP1 focus
kinetics following IR. Depletion of SENP2 severely re-
duced the accumulation of 53BP1 and RNF168 foci
throughout the time course; however,MDC1 foci initially
formed in siSENP2 and SENP2 knockout cells and then
rapidly became undetectable (Fig. 1F; Supplemental Fig.
S1I,J). The formation of bothMDC1 and 53BP1 foci at later
time points, 4 h after IR, were restored in SENP2WT- but
not SENP2C548A-complemented cells (Fig. 1I–K), suggest-
ing that deSUMOylase activity is important to the persis-
tence ofMDC1 at sites of damage and to the accumulation
of 53BP1 foci.
To address which factors are responsible for the rapid
clearance of MDC1 in SENP2-deficient cells, we first in-
vestigated RNF4, whose activity has been implicated in
MDC1 turnover (Galanty et al. 2012; Luo et al. 2012;
Yin et al. 2012; Hendriks and Vertegaal 2015; Hendriks
et al. 2015). Codepletion of RNF4 with SENP2 resulted
in focus kinetics of MDC1, RNF168, and 53BP1 similar
to that of control-treated cells (Fig. 1F–H). The pattern of
Garvin et al.
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Figure 1. SENP2 promotes DNA damage signaling and DNA repair. (A) IR colony survival in HeLa treated with siNTC or siSENP2 for
72 h. Cells were treated concurrently with 1 µg/mL doxycycline to induce siRNA-resistant forms of SENP2. n =4. (B,C ) HR (U2OS DR3-
GFP) or NHEJ (U2OS-EJ5-GFP) assays using siSENP2 or siNTC treated cells transfected with RFP, I-SceI, and SENP2WT or SENP2C548A.
GFP+ cells were normalized to RFP transfection efficiency. Percentage repair is given compared with siNTC. Western blot shows SENP2
knockdown efficiency and restoration with siRNA resistant cDNA. n =3. (D,E) SUMO/γH2AX colocalizing foci in HeLa siNTC or
siSENP2 cells fixed 1 h after 5 Gy of IR. (E) As for D with the indicated DDR factors. n= 3. (F–H) Time course of MDC1 (n= 200), GFP-
RNF168 (n =50), or 53BP1 (n= 150) foci in HeLa treated with indicated siRNA for 72 h. Representative images for 53BP1 foci at 4 h after
IR are shown. (I–K ) MDC1 and 53BP1 foci per cell, respectively, 4 h after 4 Gy of IR in siNTC or siSENP2HeLa. (K ) representative images
related to I,J, n =100 cells. (L,M ) HeLa (siNTC/siSENP2) irradiated with 4 Gy and, 0.5 h later, treated with DMSO/0.1 µMVCPi, CB-5083.
Cells were fixed at the indicated times and scored for MDC1 foci. (M ) As for L but 53BP1 foci in cells fixed at 2 h. n =100 cells.
SENP2 primes DNA repair mechanisms
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total SUMO conjugates seen following IR suggested a
similar relationship between SENP2 and RNF4. Control
cells exhibited a global increase in high-molecular-weight
SUMO conjugates, particularly for SUMO2/3, after treat-
ment (Supplemental Fig. S2A,B). Whereas in siSENP2
cells, SUMO conjugates were constitutively higher in un-
treated cells and showed only a slight increase after IR
(Supplemental Fig. S2A,B), consistent with the observa-
tion of poor DDR protein recruitment and SUMO IRIF
formation. Conjugate patterns after siRNF4+ siSENP2
codepletion resembled those seen in siNTC cells (Supple-
mental Fig. S2A,B) consistent with the near normal DDR
focus kinetics observed on codepletion. Intriguingly, loss
of the closely related protease SENP1 did not have a sim-
ilar impact on SUMO conjugates, and depleted cells
showed an exaggerated induction of SUMO conjugates
following IR (Supplemental Fig. S2C).
RNF4-dependent substrate ubiquitination is frequently
followed by processing through VCP hexameric AAA
ATPase (Dantuma et al. 2014; Torrecilla et al. 2017).
We compared the effects of proteasome (MG132) or VCP
inhibition (CB-5083) on MDC1 focus loss after IR. As pro-
teasome inhibition depletes the free Ub pool, in turn
causing a failure in Ub signaling in DSB repair (Butler
et al. 2012), we also transfected the cells with myc-Ub.
MG132 treatment resulted in increased MDC1 focus re-
tention, but, in cells expressing additional myc-Ub, focus
numbers were reduced, suggesting that Ub rather than the
proteasome is critical to MDC1 focus clearance (Sup-
plemental Fig. S2D,E). In contrast, MDC1 focus persis-
tence in the presence of VCP inhibition was unaffected
by Ub expression (Supplemental Fig. S2D,E). Moreover,
in SENP2-depleted cells the addition of CB-5083 restored
near-normal MDC1 focus kinetics and the ability to sup-
port downstream53BP1 foci (Fig. 1L,M). Thus, RNF4-VCP
contributes to the rapid MDC1 focus kinetics in SENP2-
deficient cells.
In a further test for potential nuclear pore involvement
we examined cells depleted for nuclear pore subcomplex
components and known SENP2-interacting proteins;
NUP153 and NUP107 (Goeres et al. 2011). Reduction in
NUP107 had no effect on MDC1 kinetics, and NUP153
depletionmodestly increased focus clearance (Supplemen-
tal Fig. S2F), confirming no substantial involvement of the
nuclear pore inMDC1kinetics. In contrast,whenwecode-
pleted the ligase responsible for MDC1 SUMOylation,
PIAS4 (Luo et al. 2012), we found that siPIAS4 (but not
siPIAS1) slowed MDC1 focus clearance in siSENP2 cells
(Supplemental Fig. S2G). These data consolidate the no-
tion that SUMOylation contributes to the rapid loss of
MDC1 foci observed on SENP2 loss.
MDC1 is a SENP2 substrate and hypo-SUMOylation
of MDC1 permits DDR signaling
Lysine 1840 is the main SUMO acceptor site on MDC1
(Supplemental Fig. S3A; Luo et al. 2012). To test whether
MDC1 might be a substrate of SENP2 we generated
cells expressing myc-MDC1WT or MDC1K1840R and as-
sayed focus kinetics in SENP2-depleted cells. MDC1WT
underwent accelerated clearance in siSENP2 cells, as ob-
served for endogenous MDC1. However, MDC1K1840R
was resistant to the effects of siSENP2, showing the
same increased focus retention (as reported earlier by
Luo et al. 2012) in control and siSENP2 cells (Fig. 2A,
see MDC1 and MDC1K1840R expression data in Fig. 4D,
below). Furthermore, expression of this mutant also per-
mitted the formation of downstream 53BP1 foci in
siSENP2-treated cells (Fig. 2A,B; Supplemental Fig. S3B).
Since loss of the main MDC1 SUMOylation site renders
damage signaling resistant to the effects of SENP2 repres-
sion, these data suggest that the impact of SENP2 loss oc-
curs through modification at K1840-MDC1.
We purified His6-SUMO1 and His6-SUMO2 from un-
treated and IR-treated cells (harvested 1 h after IR to cap-
ture the MDC1 clearance phase) to test the impact of
SENP2 on MDC1-SUMOylation. In untreated siSENP2
or SENP2 knockout cells, we observed an enrichment of
MDC1 in SUMO2 conjugates (Fig. 2C,D; Supplemental
Fig. S3C,D). Following exposure to IR, cells with SENP2
deficiency exhibited a reduction in SUMOylated MDC1,
whereas control cells showed an increase in SUMOylated
MDC1 (Fig. 2C,D; Supplemental Fig. S3C,D). In siRNF4+
siSENP2-codepleted cells, the IR-dependent reduction of
MDC1-SUMO2, seen in siSENP2 cells, was not observed,
and instead increased MDC1-SUMO2 was evident as in
control cells (Fig. 2C; Supplemental Fig. S3C,D). We also
confirmed directly that SENP2 could deSUMO2ylate a
fragment of MDC1 encompassing K1840 in vitro using
recombinant SENP2 catalytic domain. (Supplemental
Fig. S3E).
A conserved coiled-coil region of SENP2 contributes
to MDC1 regulation
We next assessed whether SENP2 and MDC1 interact in
cells. Using Flag-RFP-SENP2WT, we were able to detect
coimmunoprecipitation with endogenous MDC1 in un-
treated cells. The interaction was decreased within 30
min of IR (4 Gy) and did not fully return up to 5 h after
(Fig. 2E,F). The decrease in interaction was dependent on
ATM as the inhibitor KU55933 when added prior to irra-
diation prevented dissociation (Fig. 2E,F). In a search for re-
gions of SENP2 that may contribute to regulation of
MDC1-SUMO, we noted a conserved coiled-coil (CC)
domain (Supplemental Fig. S4A,B).Wegenerateda28-ami-
no-acid deletion mutant (ΔCC) domain and found no
changes in protein localization or activity (Supplemental
Fig. S4C–F). However, unlike SENP2WT, this mutant re-
tained interaction with MDC1 after exposure to IR (Fig.
2G). In complementation assays, SENP2WT permitted in-
creasedMDC1 SUMO-2ylation after IR, but cells express-
ingSENP2ΔCC failed to increaseMDC1SUMOylation (Fig.
2H).Moreover, cells complementedwith SENP2ΔCC failed
to clear MDC1 foci and were radiosensitive (Fig. 2I–K).
These data suggest that dissociation of SENP2 from
MDC1 requires the activity of ATM and the SENP2
CC domain and that dissociation is essential for the IR-
dependent SUMOylation of MDC1, focus resolution, and
proper IR repair.
Garvin et al.
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Figure 2. MDC1 is a SENP2 substrate and hypo-SUMOylation of MDC1 permits DDR signaling. (A,B) HeLa treated with siRNA and
induced with doxycycline for 72 h to express wild-type or K1840Rmyc-MDC1. Data show kinetics of foci per cell for the indicated times
after treatment with 4 Gy of IR. (B) As for A but 53BP1 foci at 2 h. n=100. (C ). HEK293FlpIn 6x-His-myc SUMO2 cells treated with the
indicated siRNA (48 h), irradiated (10 Gy), lysed 1 h later, and subjected to Ni2+ agarose purification followed by immunoblotting with
MDC1 antibodies to determine the relative enrichment in SUMO2 conjugates. (PD) Pull-downs. (D) Quantification of theMDC1 purified
by Ni2+ pull-downs in HEK293FlpIn 6xHis-myc-SUMO2 cells illustrated in Figure 2C. Relative enrichment in SUMO2-MDC1 conjugates
was determined by densitometry with the untreated siNTC sample being set as 1. n= 5. Error bars show SEM. (E) HEK293 transiently
transfectedwith Flag-RFP-SENP2WT for 48 h. Thirtyminutes preirradiation (4Gy), cellswere treatedwith 10 µMATMi orDMSO. Lysates
were made at the indicated times and immunoprecipitated with Flag agarose and blotted for endogenous MDC1 and Flag-RFP-SENP2.
(F ) Quantification of relative Flag SENP2–MDC1 interaction ratio by densitometry, the ratio was set at 1 for untreated cells. n =5. Error
bars represent SEM. (G) HEK293FlpIn myc-MDC1WT transiently transfected with Flag-SENP2WT or SENP2ΔCC and treated with doxycy-
cline for 72 h. Cells were irradiated (4 Gy) and lysed 1 h later followed by immunoprecipitation with myc-agarose. (H) HEK293FlpIn 6x-
His-myc SUMO2 cells, siRNAdepleted for SENP2 and 24-h later transfectedwith SENP2WT or SENP2ΔCC for an additional 48 h. Cell lysis
and Ni2+ pull-down was carried out as for C. (I,J). HeLa treated with siSENP2. Twenty-four hours later cells were transfected with Flag-
SENP2 for 48 h, irradiated (4 Gy), and fixed at indicated times. (G) MDC1 foci per cell weremeasured in cells costaining with Flag-SENP2.
n=50. (K ) Colony survival in IR (2 Gy) HeLa treated with siNTC, siSENP2, or siSENP2 plus doxycycline to induce expression of SENP2
mutants. n =3.
SENP2 primes DNA repair mechanisms
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Requirement for SENP2 can be bypassed by increased
K63–Ub signaling
We observed an initial association of MDC1 at DSBs in
siSENP2 cells (Fig. 1F; Supplemental Fig. S1I,J), leading
to the question of which element of the DDR is effected
by rapid loss of MDC1 from damage sites. Intriguingly, a
similar impact is seen on DSB signaling when MDC1
turnover is increased, but steady-state foci are only slight-
ly altered following loss of the DUB Ataxin-3 (ATXN3)
(Pfeiffer et al. 2017). We note that both SENP2 and
ATXN3 contribute to the longevity ofMDC1 foci and col-
ony survival in response to IR (Supplemental Fig. S5A,B),
so that together these observations suggest that MDC1
residency, or quality of MDC1 at sites of damagemay pro-
mote downstream signaling. MDC1 is involved in two
positive feedback loops that may require its prolonged as-
sociation. It contributes to signal amplification of γH2AX
around DNA break sites with MRN and ATM (Stucki
et al. 2005; Chapman and Jackson 2008; Savic et al.
2009) and the amplification of K63–Ub linkages on His-
tone H1 and L3MBTL2 (Thorslund et al. 2015; Nowsheen
et al. 2018) with RNF8 and, downstream, RNF168 (for re-
view, see Panier and Boulton 2014). Since we observed no
loss of γH2AX foci in SENP2-deficient cells (Supplemen-
tal Fig. S1A,I,J), we tested whether insufficient K63-Ub
generation contributes to DDR signal failure by manipu-
lating the K63-Ub machinery. Overexpression of RNF8,
which catalyzes the initial K63-Ub contribution (Lok
et al. 2011; Thorslund et al. 2015), and the depletion of
the K63–Ub-specific Ub protease BRCC36 (depletion of
which increases K63-Ub at sites of damage) (Shao et al.
2009) were capable of restoring 53BP1 foci in siSENP2
cells (Supplemental Fig. S5C–E). These data suggest that
normal turnover kinetics of MDC1 at damage sites is
needed for sufficient Ub conjugate generation.
RNF4-VCP is responsible for the IR sensitivity
of SENP2-depleted cells
Prompted by our findings that RNF4 is responsible for
rapid MDC1 focus kinetics in siSENP2-depleted cells,
we next assessed whether RNF4 contributes to their ra-
diosensitivity. Depletion of RNF4 or SENP2 individually
increased cell sensitivity to IR, but codepletion resulted
in IR resistance similar to siNTC cells (Fig. 3A). Expres-
sion of RNF4WT restored resistance to RNF4-depleted
cells, however, critically, on a siSENP2+ siRNF4 back-
ground reintroduction of RNF4WT resulted in IR sensitiv-
ity (Fig. 3B), demonstrating the toxicity of RNF4 in
siSENP2 cells. Complementation with RNF4 proteins
that reduce interaction with its Ub loaded E2 conjugating
enzyme, prevent RNF4 dimerization or interaction with
SUMO (Plechanovova et al. 2012; Kung et al. 2014;
Rojas-Fernandez et al. 2014) allowed survival on siRNF4
+ siSENP2 backgrounds but not cells treated with siRNF4
alone (Fig. 3B). We confirmed the corollary of these find-
ings; that SENP2 protease activity contributes to the tox-
icity of IR in siRNF4 cells (Fig. 3C). Moreover VCP
inhibition restored IR resistance to siSENP2 cells (Fig.
3D). Thus the STUbL function of RNF4 and VCP activity
contributes to the IR sensitivity of SENP2 depleted cells.
Among the SENP family of SUMO proteases SENP2 is
alone in contributing significantly to the lethality of IR
in RNF4-depleted cells (Supplemental Fig. S5F). Together,
our data reveal a strong reciprocal relationship between
RNF4 and SENP2 in the cellular response to IR,
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Figure 3. RNF4-VCP is responsible for the
IR sensitivity of SENP2-depleted cells.
(A) IR colony survival in HeLa treated with
the indicated siRNA for 72 h. (Right panel)
Western blot of siRNA depletions. (B) Colony
survival in HeLaFlpIn RNF4 treated with the
indicated siRNA and doxycycline to induce
expression of RNF4 and its mutants for 72 h
prior to 2 Gy IR, n=3. Western blot is shown
below. Note that RNF4 antibody will also
detect exogenous protein. (C ) Colony sur-
vival in HeLaFlpIn SENP2 treated with indi-
cated siRNA and doxycycline to induce
expression of SENP2 and its mutants for
72 h prior to 2 Gy IR. n =3. Western blot is
shown below. (D) Colony survival of HeLa
treated with the indicated siRNAs for 72 h
and 4 Gy IR. Thirty minutes after irradiation,
cells were treated with DMSO and 0.1 µM
VCP inhibitor CB-5083 for an additional
90 min prior to plating for colonies in fresh
media n=3.
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consistent with their opposing influences on MDC1 in
DSB damage signaling.
SENP2 is not relevant to S-phase clearance of MDC1
Weexpected to see a role for SENP2 in regulatingMDC1at
repair foci throughout the cell cycle.However,whenwe la-
beled cells with a nucleotide analog to differentiate
S-phase cells, we found that SENP2depletion hadno influ-
ence on MDC1 in S-phase marked cells (Fig. 4A–C). Ex-
pression of the MDC1K1840R SUMO site mutant results
in cellular IR sensitivity due to a failure of the mutant to
clear from sites of DNA damage (Luo et al. 2012). We
confirmed these data (Fig. 4D,E), but also challenged cells
with olaparib and CPT, agents that require HR repair
for resistance, and found that MDC1K1840R did not in-
crease sensitivity to these agents (Fig. 4F,G). Moreover,
the MDC1K1840R mutant had no negative impact on
RAD51 focus formation in S-phase cells (Fig. 4H). While
MDC1K1840R expression increased 53BP1 focus numbers
in EdU− cells, as reported previously (Luo et al. 2012), it
did not alter 53BP1 focus number in EdU+ cells (Fig. 4I).
Moreover, unlike the response to IR, codepletion of
RNF4 and SENP2 did not improve survival of cells
challenged by olaparib or CPT and did not substantially
improve HR reporter activity or RAD51 focus accumula-
tions over single depletions (Fig. 4J–N). We conclude that
S-phase cells turn over MDC1 from broken DNA ends in-
dependently of the major MDC1 SUMO acceptor site and
of SENP2, suggesting that the role of SENP2 in HR repair
occurs in another pathway.
HR is highly sensitive to the supply of SUMO
Since we observed increased high molecular weight
SUMO conjugates in untreated cells depleted of SENP2
(Supplemental Fig. S2A) we speculated that SENP2 loss
may disable HR through reduced availability of SUMO
for conjugation. We overexpressed conjugation proficient
and deficient SUMO in siSENP2 cells and examined sur-
vival in response to IR, CPT, or olaparib. We also assessed
MDC1 foci 4 h after IR and RAD51 foci in S-phase cells.
SUMOsupplementation had no influence on IR resistance
nor onMDC1 foci (Fig. 5A–C), but conjugation-competent
SUMO2 improved CPT and olaparib resistance and re-
stored RAD51 foci in SENP2-depleted cells (Fig. 5D–F). In-
triguingly SENP2 depletion had no impact on RPA focus
accrual, suggesting a role for SENP2 in RAD51 loading
but not DNA end resection (Supplemental Fig. S5G). To
test the hypothesis that differential requirements for
SUMO availability exist between different repair mecha-
nisms we performed a partial depletion of SUMO2/3 (Fig.
5G,H). Remarkably, partial SUMO2/3 depletion resulted
in CPT and olaparib, but not IR, sensitivity and impaired
HR, but not NHEJ in integrated repair assays (Fig. 5I,J),
indicating that the HR pathway is more sensitive to
SUMOavailability.We further explored this inHAP1 cells
(which, unlikeHeLa, haveanabundantpool of free SUMO)
that had been enriched in G1, S, orM phases of the cell cy-
cle. In G1 there was no difference in free SUMO2/3 levels
between wild-type and SENP2 knockout cells, while in
S- and M-phase enriched cells we noted lower levels
of free SUMO in SENP2 knockout cells versus wild-type
cells (Fig. 5K). Therefore SENP2 is important formaintain-
ing a free SUMO pool during stages of the cell cycle in
which HR occurs. Many HR factors are known to be
SUMO modified (Garvin and Morris 2017). Increasing
available SUMO circumvents the loss of SENP2 in HR
sensitivity; therefore, we could not use the 6× histidine-
SUMO pull-down assays used previously to detect
MDC1 SUMOylation. Therefore, to measure endogenous
SUMO association of HR factors, we used immobilized
SIM peptides to enrich SUMO-associated factors from ly-
sates derived from control or CPT-treated HAP1 cells.
We confirmed that the SIM peptide was enriching
SUMO2/3 by using mutant peptides lacking a functional
SIM (Supplemental Fig. S5H).We probed these pull-downs
against a number of HR factors and detected increased
SUMO association following CPT treatment with BLM,
SMARCAD1, KAP1, and RPA70 antibodies in wild-type
HAP1 cells. However, in SENP2 knockout cells, the
CPT-dependent increase in SUMO association was seen
withKAP1andRPA70butnotwithBLMandSMARCAD1
(Supplemental Fig. S5H).Whilewe tested only a small pan-
el of HR factors, these results suggest that CPT-dependent
changes in SUMOylation/SUMO association are disrupt-
ed in SENP2-deficient cells in at least two HR factors. In-
triguingly, BLM SUMOylation has been shown to be
important for RAD51 loading (Ouyang et al. 2009), a step
that is deficient in SENP2 disrupted cells (Fig. 4M).
High levels of SENP2 disrupt DSB repair
The SENP2 gene maps to chromosome 3q26-29, a region
commonly amplified in epithelial cancers of the lung, ova-
ries, esophagus, and head and neck (Supplemental Fig.
S6A,B; Qian and Massion 2008; Cancer Genome Atlas
Network 2015). In lung cancer, high SENP2mRNA levels
correlate both with copy number and reduced patient sur-
vival (Supplemental Fig. S6C,D).
The 3q amplification carries two more genes involved
in DNA repair: the Ub ligase RNF168, and the deubiquiti-
nating enzyme USP13 (Supplemental Fig. S6E), which
contribute to DNA-damage signaling (Doil et al. 2009;
Stewart et al. 2009; Nishi et al. 2014; Chroma et al.
2017; Li et al. 2017). We compared the influence of high
expression of each repair gene in HeLaFlpIn stable doxycy-
cline-inducible cells. Of the three genes, SENP2 had the
greatest influence on IR resistance, while increased
SENP2 and USP13 reduced CPT resistance (Supplemental
Fig. S6F–H)
Since our data show a critical role for SENP2 in DSB re-
pair, we explored whether increased SENP2 expression al-
ters repair. We found that elevation of SENP2 expression
resulted in increased 53BP1 and MDC1-dependent resis-
tance to IR (Fig. 6A,B) and was accompanied by persistent
MDC1 foci at 2 h after IR (Fig. 6C,D). With the exception
of SENP6, no other SENP expression slowedMDC1 clear-
ance (Supplemental Fig. S6I,J). High expression of SENP2
also induced a 2.5-fold increase inNHEJmeasured froman
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Figure 4. SENP2 is not relevant to S-phase clearance of MDC1. (A,B) HeLa treated with siNTC (black) or siSENP2 (blue) for 72 h, pulsed
with 10 µM EdU 1 h prior to IR (4 Gy). Cells were fixed at indicated times and subjected to Click-It labeling with 647 nm azide to detect
EdU incorporation into nascent chromatin. MDC1 foci per cell in EdU-negative (A) and EdU-positive (S phase) (B) cells. Fifty cells were
scored per condition from a total of three experiments. Error bars represent SEM. (C ) Representative images relating toA and B. (D) West-
ern blot showing MDC1 knockdown and expression in HeLaFlpIn myc-MDC1 wild type or K1840R (KR). (E–G) HeLaFlpIn myc-MDC1WT
(blue) and K1840R (green) cells siRNA depleted for endogenous MDC1 and treated with doxycycline to induce MDC1. After 72 h, cells
were treated with 2 Gy of IR (E), 10 µM olaparib (F ), or 2.5 µM CPT (G) for 2 h and subjected to colony survival analysis. n=3. (H) HeLa
myc-MDC1WT (blue) and K1840R (green) cells siRNA depleted for endogenous MDC1 and treated with doxycycline to induce myc-
MDC1. After 72 h, cells were pulsed with 10 µM EdU 1 h prior to 4 Gy of IR. Cells were fixed 2 h after IR and subjected to Click-It labeling
with 647-nm azide to detect EdU incorporation into nascent chromatin and stainedwith RAD51. n =100 EdU+ cells. (I ) HeLa treated with
doxycycline to induce expression of myc-MDC1WT or K1840R for 72 h. One hour prior to 4 Gy of IR, cells were pulsed with EdU and fixed
2 h later. Cells (100 from a total of three experiments) were scored for 53BP1 foci per cell in EdU−/+ cells. (J,K). Colony survival in HeLa
treated with indicated siRNA and 10 µM olaparib for 2 h (J) or 2.5 µM CPT for 2 h (K ). n=3. (L) U2OS-DR3 homologous recombination
reporter cells treated with siRNA for 24 h prior to transfection with I-Sce-I nuclease and RFP (to control for transfection efficiency) for a
further 48 h. The percentage of RFP/GFP-positive cells relative to siNTC is shown for three experiments. (M ) HeLa depleted for indicated
siRNA for 72 h were pulsed with 10 µM EdU for 1 h prior to 4 Gy of irradiation. Cells were fixed 4 h later and RAD51 foci counted in EdU-
positive cells. n=100. (N) Images relating toM.
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Figure 5. HR is sensitive to the supply of SUMO. (A) Colony survival after 2 Gy IR in HeLaFlpIn 6xHis-myc SUMO in siNTC/siSENP2-
depleted cells. GA indicates diglycine→ alaninemutants in SUMO isoforms that prevent conjugation. n =3. (B) HeLa treated with siRNA
for 24 h before transfectionwithmyc-SUMO; 48 h later cells were treatedwith 4Gy, fixed at 4 h, immunostained, and scored forMDC1 in
myc-SUMO expressing cells. n =100. (C ) Western blot of SUMO conjugates relating to (A,B). (D,E) As for A but using 1 µM CPT (D) or
10 µM olaparib (E) for 2 h before plating for colony survival. n =3. (F ). HeLa treated with siRNA for 24 h before transfection with myc-
SUMO for 48 h. Cells were incubated with 10 µM EdU 30 min prior to 4 Gy of IR, fixed at 4 h, and immunostained for RAD51 and
myc to detect myc-SUMO-expressing cells. n =100. Only EdU+ myc-SUMO-positive cells were counted for RAD51 focus number.
(G) Western blot showing partial depletion of SUMO2/3 conjugates in HeLa. (H) Colony survival in HeLa depleted with siNTC or
siSUMO2/3 followed by treatment with 2 Gy of IR, 1 µM CPT, or 10 µM olaparib. (I). Western blot showing SUMO2/3 knockdown.
(J) U2OSHR andNHEJ reporters treatedwith siNTCor siSUMO2/3 and transfectedwith i-Sce-I and RFP for 72 h. HR andNHEJ efficiency
was set at 100% for siNTC. (K ) HAP1 cells synchronized into G1-, S-, and M-enriched populations; lysed; and probed for free SUMO2/3.
Cyclin A1 is a late S-phase marker.
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integrated substrate (Fig. 6E,F). Thus, increased SENP2 re-
sults in slowerMDC1clearance correlatingwith increased
IR resistance and improved NHEJ. Increased expression of
SENP2 reduces high-molecular-weight SUMO conjugates
(Supplemental Fig. S4E,F), leading us to speculatewhether
persistent removal of SUMOmay also influenceHR. High
SENP2 expression resulted in reduced HR reporter prod-
uct, reduced RAD51 foci, and reduced CPT resistance
(Fig. 6G,H). Examination of chromosome aberrations in
cells acutely overexpressing SENP2 showed increased
chromosomal gaps following IR, suggesting an overall re-
duced repair abilitydespite improved IR resistance (Fig. 6I).
Discussion
The sequential action of PTMs is essential for the proper
cellular response to DSBs. While cross-talk between
SUMOylation and ubiquitination is important for the in-
tegration of signaling cues for the response, the extent of a
role for deSUMOylation was poorly defined. Here we pro-
vide evidence that deSUMOylation is required prior to the
onset of DSB signaling to govern correct PTM timing fol-
lowing damage. Mechanistically, we identified two dis-
tinct pathways in which deSUMOylation is required
(Supplemental Fig. S7A,B).
We show that interaction betweenMDC1 and SENP2 in
untreated cells is associated with MDC1-hypoSUMOyla-
tion and with Ub signaling in the damage response. In
the absence of SENP2, PIAS4-mediated SUMOylation fa-
cilitates rapid RNF4-VCP-mediated MDC1 turnover and
a failure of downstream signaling. MDC1 SUMOylation
and RNF4-processing is induced on chromatin (Luo et al.
2012), so one question arising from our study is why con-
stitutive interaction with a SUMO protease is needed?
MDC1-SUMO is detected in untreated cells (Galanty
et al. 2012; Luo et al. 2012; Yin et al. 2012; Vyas et al.
2013; Hendriks and Vertegaal 2015; Hendriks et al.
2015), suggesting a constitutive propensity to modifica-
tion even in the presence of SENP2. Thus, interaction
with a SUMOproteasemay be needed to prevent the accu-
mulation of a heavily modified protein at DSBs capable of
driving its own removal.
We show that DDR signaling via ATM and conserved
coiled-coil region (amino acids 203–228) in SENP2 is need-
ed to release MDC1–SENP2 interactions following IR and
to allow subsequent MDC1 SUMOylation needed for its
eventual clearance from damaged chromatin. The SENP
family of SUMO proteases contain relatively few func-
tionally annotated domains outside of the C-terminal cat-
alytic regions (Mukhopadhyay and Dasso 2007). How the
coiled-coil allows IR-regulated dissociation remains to be
discovered. Its conservation in evolution as far as chicken
and zebrafish (Supplemental Fig. S4B) suggests an impor-
tant role for the motif.
We found that the role of SENP2 in HR repair has no re-
lationship with the MDC1-processing pathway, that
MDC1 foci are cleared in S-phase cells at the same
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Figure 6. SENP2overexpressiondisrupts re-
sponses to DSBs. (A,B) HeLaFlpIn SENP2WT
mock or doxycycline (to induce SENP2 ex-
pression) for 72 hwere treated with indicated
dose of IR and subjected to colony survival
analysis. (B) Colony assay performed as for A
but with siRNA transfection concurrent
with doxycycline addition. IR =2 Gy. n=3.
(C,D) HeLa transfected with SENP2WT for 48
h prior to 4 Gy IR and fixation 2 h later.
MDC1 foci per cell were scored in Flag-
SENP2-positivecells.n=100. (D)Representa-
tive images of C. (E,F ) HR and NHEJ U2OS
reporters expressing RFP or RFP-SENP2 and
I-Sce1GFP-positive cells were normalized to
RFP-transfection efficiency. Percentage re-
pair is givencomparedwithNTC. (F )Western
blot showing expression of RFP-SENP2.n= 4.
(G) HeLa transfected with SENP2WT for 48 h
prior to30minofEdUpulse and4Gyof IR fol-
lowedbyfixation4hlater.One-hundredEdU/
Flag-SENP2-positive and 100 EdU/untrans-
fected cellswere scored forRAD51 foci across
threeexperiments. (H)AsforAbutusing2hof
treatment of 2.5 µMCPT for 2 h prior to plat-
ing. (I ) HeLa SENP2WT or HeLa treated with
doxycycline for 72hprior to IR2Gy.Eighteen
hours later, cells were treated with colcimid
for 6 h and processed for metaphase spread
analysis. Data show percentage metaphases
withchromosome/chromatidgapsfromthree
experiments. Error bars represent SEM.
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kineticswith orwithout SENP2, and thatMDC1 inwhich
themain SUMO acceptor site is mutated is also cleared in
S-phase cells at the same rate aswild-type protein.MDC1-
depleted cells complemented with the K1840R mutant
were IR-sensitive, as described previously (Luo et al.
2012); however, they exhibit normal levels of RAD51
foci in S-phase cells and exhibit both olaparib and CPT re-
sistance, suggesting adequateHR repair. A previous report
correlated RNF4 activation with altered MDC1 kinetics
in S phase (Luo et al. 2015). We suggest that the altered
MDC1 kinetics in S-phase RNF4 depleted or mutant cells
may be due to indirect regulation by RNF4 through other
aspects of DNA repair. However, the previous finding that
MDC1-K1840R significantly impacts HR repair (Luo et al.
2012) was not supported by the current study. We cannot
rule out that another SUMO site is significant, although,
if such a site were SUMO-modified for RNF4 interaction,
it would differ in its response to SENP2.
Instead, measures of HR repressed in SENP2-deficient
cells are rescued by the expression of exogenous
SUMO2/3. SUMO conjugation is required for both main
pathways of DSB repair so that a total loss of SUMO avail-
ability/conjugation restricts both mechanisms (Galanty
et al. 2009;Morris et al. 2009).What is striking in our find-
ings is evidence for a level of SUMO availability at which
NHEJ can function but HR cannot. The degree to which
each repair process captures available SUMO is not
known.Thedifferential requirementmay reflect the great-
er number of SUMOylated factors in HR over NHEJ, a
greater need for group modification in HR, or a greater
need for the promotion of particular interactions, for ex-
ample, between BLM, RPA, and RAD51 (Eladad et al.
2005; Ouyang et al. 2009; Dou et al. 2010; Galanty et al.
2012; Bologna et al. 2015; Hendriks and Vertegaal 2016;
Garvin and Morris 2017). Alternatively, cells in S phase
may have a greater need for available SUMO in replicative
processes, reducing availability for HR, which is some-
what supported by our data (Fig. 5K).
In the HeLaFlpIn cells used in the current study we de-
tected no free SUMO pool and no accumulation of exoge-
nous SUMO2 in a free SUMO2/3 pool, suggesting that the
increase in SUMO2 availability was immediately cap-
tured within conjugates. In some cell types, the vast ma-
jority of SUMO exists in conjugates; for example,
shifting from 93% of SUMO2/3 in conjugates to 96%
and 98% on MG132 and heat shock, respectively, in
HEK293T cells (Hendriks et al. 2018). In these contexts,
induced SUMO conjugation in stress responsesmay be re-
liant on SUMO synthesis and recycling from SUMOy-
lated proteins.
We also show that acute, high-level expression of
SENP2 results in increasedNHEJ correlatingwith extend-
ed MDC1 focus longevity and 53BP1-dependent IR
resistance, consistent with extended defense of MDC1-
SUMO. SENP2 overexpression also reduces global
SUMO conjugates, and we speculate strips SUMO from
HRproteins during thedamage response. In bothpathways
SENP2 levels dramatically influence repair outcomes.
Many cancers have altered SUMOylation (Seeler and
Dejean 2017) and SENP2 transcription can be up-regulat-
ed by NF-κb, which is commonly activated during cancer
development (Lee et al. 2011). SENP2 is one of several
genes on the amplified region of chromosome 3q with
the capacity to influence survival to DNA-damaging ther-
apeutics. Evidence of SUMO-pathway addiction has been
found in Myc- and Ras-driven cancers (Kessler et al. 2012;
Yu et al. 2015), while those with low SUMOylation may
be sensitive to further targeting of the SUMO system (Lic-
ciardello et al. 2015). Differential needs for SUMO conju-
gation and deconjugation therefore could expose tumor-
specific vulnerabilities. SUMO E1 and E2 inhibitors
have been described (Lu et al. 2010; Kumar et al. 2016;
He et al. 2017), and our data imply that partial SUMOcon-
jugation inhibition could disable HR but not NHEJ, in-
creasing sensitivity to HR-directed therapies. Common
3q-amplified tumors such as those in the aerodigestive
track cancers often receive postoperative radiotherapy,
so further investigation into targeting altered DNA repair
thatmayoccur as a result of 3q amplification iswarranted.
In summary, the need for the SUMO protease, SENP2,
in aspects ofmammalianDSB repair presented here reveal
unexpected requirements for SUMO deconjugation and
its regulation in the DNA damage response. They place
the need for the activity largely in undamaged cells before
the stress of DSBs occurs. We found deSUMOylation by
SENP2 first prevents engagement of RNF4-VCP with
MDC1, restricting an “over before it has begun” repair re-
sponse and secondly promotes SUMO supply, critical to
the completion of HR. Increased SENP2 expression there-
fore dramatically dysregulates DSB repair mechanisms.
Materials and Methods
Colony survival assays
Cells were plated at 2.5 × 105 cells per milliliter in a 24-well plate.
For siRNA transfections, cells were transfected 24 h after plating
for an additional 48 h. For overexpression, cells were treated with
1 µg/mL doxycycline for 72 h. Cells were treatedwith the indicat-
ed dose of DNA-damaging agent prior to plating at limiting dilu-
tion in six-well plates to form colonies and grown for 10 d (three
wells per technical repeat). Colonieswere stainedwith 0.5%crys-
tal violet (BDH Chemicals) in 50%methanol and counted. Colo-
ny survival was calculated as the percentage change in colonies
versus untreated matched controls. Graphs shown are combined
data fromaminimumof three independent experiments and error
bars show SEM.
Transfections
siRNA transfections (10 nM) were performed using Dharmafect1
(Dharmacon) and DNA plasmids using FuGENE 6 (3 µL of
FuGENE:1 µg of DNA) (Promega) following the manufacturer’s
protocols. SMARTPoolswere fromDharmacon and individual se-
quences were from Sigma. See Supplemental Table 3 for siRNA
sequences. Cells were grown for 48–72 h after transfection before
treatment and harvesting.
Drug treatments
Irradiation was performed with a Gamma-cell 1000 Elite (Cs137)
radiation source. The following chemicals were used: 0.1 µM
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CB-5083/VCPi, 10 µM olaparib (Selleck Chemicals), 1 µM CPT,
10 µM MG132, 0.05 µg/mL colcimid, 1 µg/mL aphidocolin, 2
mM thymidine, 150 ng/mL nocodazole (Sigma), 10 µM EdU
(Life Technologies), and KU55933 (Abcam, ab120637).
NHEJ and HR assays
U2OS-DR3-GFP (gene conversion), and U2OS-EJ5-GFP (NHEJ)
were a generous gift from Jeremy Stark (City of Hope, Duarte,
USA). U20S reporter cell lineswere simultaneously cotransfected
with siRNA using Dharmafect1 (Dharmacon) and DNA (RFP, or
Flag-SENP2 and I-Sce1 endonuclease expression constructs) us-
ing FuGene6 (Promega), respectively. After 16 h, the media was
replaced and cells were grown for a further 48 h before fixation
in 2% PFA. RFP and GFP double-positive cells were scored by
FACS analysis using a CyAn flow cytometer and a minimum of
10,000 cells counted. Data was analyzed using Summit 4.3 soft-
ware. Each individual experiment contained three technical re-
peats and normalized to siRNA controls or wild-type-
complemented cells. Graphs shown are combined data from a
minimum of three independent experiments and error bars
show standard error.
Immunofluorescence
Cells were plated on 13-mm circular glass coverslips at a density
of 5 × 104 cells per milliliter and treated as required. For RPA and
RAD51, cells were labeled with 10 µM EdU 1 h prior addition of
DNAdamage. For staining, cells were pre-extracted in CSK buffer
(100 mM sodium chloride, 300 mM sucrose, 3 mM MgCl2, 10
mMPIPES at pH 6.8) for 1 min at room temperature, For all other
stainings, cells were first fixed in 4%PFA and permeabilizedwith
0.5% Triton X-100 in PBS. After blocking in 10% FCS, cells were
incubated with primary antibody for 1 h (unless stated otherwise)
and with secondary Alexa fluor antibodies for 1 h. EdU was visu-
alized byClick-iT chemistry according to themanufacturer’s pro-
tocols (Life Technologies) with Alexa-647-azide. The DNA was
stained using Hoechst at 1:20,000. In some images, the DNA
stain was drawn around (but not shown) to illustrate the location
of the nucleus.
With the exception of Figure 1, G and H, all immunofluores-
cent staining was imaged using the Leica DM6000B microscope
using a HBO lamp with a 100-Wmercury short-arc UV bulb light
source and four filter cubes (A4, L5, N3, and Y5) to produce exci-
tations at wavelengths 360, 488, 555, and 647 nm, respectively.
Images were captured at each wavelength sequentially using
the plan apochromat HCX 100×/1.4 oil objective at a resolution
of 1392×1040 pixels. Detection of SUMO IRIF was performed ac-
cording to Morris et al. (2009).
Cell lines
The growth conditions and vendors for all cell lines are detailed in
Supplemental Table 2. FlpIn stable cell lineswere generated using
HEK293TrEx-FlpIn (Invitrogen) and HeLaFlpIn (a gift from Grant
Stewart, University of Birmingham) cells transfected with
pcDNA5/FRT/TO-based vectors and the recombinase pOG44
(Invitrogen) using FuGene6 (Promega). After 48 h, cells were
placed into 100 µg/mL hygromycin selection medium and grown
until colonies formed on plasmid transfected plates but not con-
trols. HAP1 SENP2 knockout cells (128-base-pair deletion in
exon 3, HZGHC002974c003) and parental cells were from Hori-
zon Discovery and were cultured according to manufacturer’s
instructions.
Coimmunoprecipitation
HEK293FlpIn myc-MDC1WT were seeded on 10-cm plates in the
presence of 1 µg/mL doxycycline for 24 h prior to transfection
with 3 µg of Flag-SENP2 per plate for a further 48 h. Cells were
treatedwith 4 Gy of IR and pelleted 1 h later in cold PBS. Cell pel-
lets were lysed in 0.5 mL hypotonic buffer (10 mM HEPES at pH
7.8, 10 mM KCl, 1.5 mMMgCl2, 340 mM sucrose, 10% glycerol
0.2% NP40, protease, phosphatase inhibitor cocktails) for 5 min
on ice and centrifuged at 3000 rpm for 3 min. The nuclear pellet
was lysed in nuclear buffer (0.05% NP40, 50 mM Tris pH 8, 300
mM NaCl, protease and phosphatase inhibitor cocktails) and ro-
tated for 30 min at 4°C. Lysates were briefly sonicated and clari-
fied at 12,000 rpm for 10 min to remove debris. Cleared lysates
(0.9 mL) were incubated with either myc (Thermo Fisher) or M2
(Sigma) agarose (20-µL packed bead volume) for 16 h at 4°C
with rotation. Beads were washed three times with NETN buffer
(100 mM NaCl, 20 mM Tris-HCl at pH 8, 0.5 mM EDTA, 0.5%
NP40) before elution with 4× Lamelli buffer.
Supplemental methods
Methods describing cloning, in vitro assays, pull-downs, meta-
phase spreads, and cell cycle synchronization are in the Supple-
mental Material. Supplemental Tables 1–4 contain details on
antibodies, cell lines, siRNA, and oligonucleotide sequences,
respectively.
Statistics
Unless stated otherwise, all statistical analysis was by two-sided
Student’s t-test throughout (P <0.05 [∗], P <0.01 [∗∗], P<0.005
[∗∗∗], and P< 0.001[∗∗∗∗]). All center values are given as the
mean, and all error bars are SEM. Data were analyzed using
Graphpad Prism 7.03.
Quantification
AllWestern blot or image analysis for quantificationwas done us-
ing ImageJ unless specified otherwise.
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